Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions

Pharmacological Reports

Volumn 63, Issue 2, 2011, Pages 337-347

  Rogosnitzky, Moshe ^a   Danks, Rachel ^b  

^a MedInsight Research Institute   (Israel)

^b MedInsight Research Institute   (United Kingdom)

Author keywords

Alopecia; Anemia; Cancer; Cepharanthine; Leukopenia; Multiple myeloma; Sarcoidosis; Snakebites

Indexed keywords

8 DIFLUOROMETHOXY 1 ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 4 OXO 3 QUINOLINECARBOXYLIC ACID; ALPHA TOCOPHEROL; BUTYLATED HYDROXYANISOLE; CEPHARANTHINE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; KALLIKREIN; KETOTIFEN; MEMBRANE LIPID; METHYLGLYOXAL; METHYLPREDNISOLONE; PACLITAXEL; PROTEIN KINASE C; SQUARIC ACID DIBUTYL ESTER; TROLOX C; TUMOR NECROSIS FACTOR ALPHA; VENOM ANTISERUM; VINBLASTINE; VINCRISTINE; VINDESINE;

ACUTE DISEASE; ALOPECIA; ALOPECIA AREATA; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHEMICAL STRUCTURE; CHRONIC DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME REPRESSION; HISTAMINE RELEASE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; JAPAN; KIDNEY CARCINOMA; LEUKOPENIA; LIPID PEROXIDATION; MALARIA; METASTASIS; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PROSTATE CANCER; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REFRACTORY ANEMIA; REVIEW; SARCOIDOSIS; SEPTIC SHOCK; SNAKEBITE; THROMBOCYTE AGGREGATION; TREATMENT DURATION; XEROSTOMIA;

EID: 79955940323     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70500-X     Document Type: Review

References (79)

1. Abe T, Koike K, Ohga T, Kubo T, Wada M, Kohno K: Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. Br J Cancer, 1995, 72, 418-423.
2. Akiba S, Kato E, Sato T, Fujii T: Biscoclaurine alkaloids inhibit receptor-mediated phospholipase A2 activation probably through uncoupling of a GTP-binding protein from the enzyme in rat peritoneal mast cells. Biochem Pharmacol, 1992, 44, 45-50.
3. Asaumi J, Nishikawa K, Matsuoka H, Iwata M, Kawasaki S, Hiraki Y: Direct antitumor effect of cepharanthin and combined effect with adriamycin against Ehrlich ascites tumor in mice Anticancer Res, 1995, 15, 67-70.
4. Asukai K, Kimura A, Gorai I, Uemura T, Minaguchi H: Effects of massive administration of cepharanthin on chemotherapy-induced leukopenia. Gan To Kagaku Ryoho, 1989, 16, 2583-2587. (Pubitemid 19221739)
5. Azuma M, Aota K, Tamatani T, Motegi K, Yamashita T, Ashida Y: Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor kappaB: a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjögren's syndrome patients. Arthritis Rheum, 2002, 46, 1585-1594. (Pubitemid 34620206)
6. Baba M, Okamoto M, Kashiwaba N, Ono M: Anti-HIV-1 activity and structure-activity relationship of cepharanoline derivatives in chronically infected cells. Antivir Chem Chemother, 2001, 12, 307-312. (Pubitemid 34168779)
7. Chea A, Hout S, Bun S, Tabatadze N, Gasquet M, Azas N: Antimalarial activity of alkaloids isolated from Stephania rotunda. J Ethnopharmacol, 2007, 112, 132-137. (Pubitemid 46702419)
8. Graham RM, Guest JD, Thompson JW, Webster KA, Vanni S: Cepharanthine reverses multidrug resistance sensitizing neuroblastoma cell lines to vincristine-induced cell death. Presented at AACR, 2010.
9. Ebina T, Ishikawa K, Murata K: Antitumor effect of Cepharanthin in the double grafted tumor system. Gan To Kagaku Ryoho, 1990, 17, 1165-1171. (Pubitemid 20378243)
10. Edashige K, Utsumi T, Utsumi K: Inhibition of 12-O-tetradecanoyl phorbol-13-acetate promoted tumorigenesis by cepharanthine, a biscoclaurine alkaloid, in relation to the inhibitory effect on protein kinase C. Biochem Pharmacol, 1991, 41, 71-78.
11. Enokida H, Gotanda T, Oku S, Imazono Y, Kubo H, Hanada T: Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line. Jpn J Cancer Res, 2002, 93, 1037-1046. (Pubitemid 35154271)
12. Fujii K, Takasugi S, Toki N: Effect of cepharanthine on neuro-humoral excitatory responses of gastric movement in dog. Jpn J Physiol, 1981,31, 613-623. (Pubitemid 12219841)
13. Fujimura T, Shibata H, Maekawa I, Furusawa S, Kawauchi H, Sasaki K: Reversal of resistance to doxorubicin with cepharanthine in murine P388 leukemia cells. Jpn J Pharmacol, 1990, 54, 464-467.
14. Furusawa S, Wu J, Fujimura T, Nakano S, Nemoto S, Takayanagi M: Cepharanthine inhibits proliferation of cancer cells by inducing apoptosis. Methods Find Exp Clin Pharmacol, 1998 Mar, 20, 87-97 (Pubitemid 28210504)
15. Furusawa S, Wu J: The effects of biscoclaurine alkaloid cepharanthine on mammalian cells: implications for cancer, shock, and inflammatory diseases. Life Sci, 2007, 80, 1073-1079. (Pubitemid 46241220)
16. Goto M, Zeller WP, Hurley RM: Cepharanthine (biscoclaurine alkaloid) treatment in endotoxic shock of suckling rats. J Pharm Pharmacol, 1991, 43, 589-591.
17. Graham R: Cepharanthine reverses multidrug resistance sensitizing neuroblastoma cell lines to vincristine-induced cell death. AAOR 101st Annual Meeting 2010.
18. Gülçin I, Elias R, Gepdiremen A, Chea A, Topal F: Antioxidant activity of bisbenzylisoquinoline alkaloids from Stephania rotunda: cepharanthine and fangchinoline. J Enzyme Inhib Med Chem, 2010, 25, 44-53.
19. Halicka D, Ita M, Tanaka T, Kurose A, Darzynkiewicz Z: Biscoclaurine alkaloid cepharanthine protects DNA in TK6 lymphoblastoid cells from constitutive oxidative damage. Pharmacol Rep, 2008, 60, 93-100. (Pubitemid 351586547)
20. Harada K, Supriatno, Yamamoto S, Kawaguchi S, Yoshida H, Sato M: Cepharanthine exerts antitumor activity on oral squamous cell carcinoma cell lines by induction of p27Kip1. Anticancer Res, 2003, 23, 1441-1448. (Pubitemid 36754112)
21. Harada K, Ferdous T, Itashiki Y, Takii M, Mano T, Mori Y: Cepharanthine inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing expression of vascular endothelial growth factor and interleukin-8. Int J Oncol, 2009, 35, 1025-1035.
22. Hashizume T, Yamaguchi H, Sato T, Fujii T: Suppressive effect of biscoclaurine alkaloids on agonist-induced activation of phospholipase A2 in rabbit platelets. Biochem Pharmacol, 1991, 41, 419-423.
23. Hibasami H, Takaji S, Murata T, Nakashima K: Cepharanthine potentiates the antitumor effect of methyl-glyoxal bis (cyclopentylamidinohydrazone) on human leukemia cells. Anticancer Res, 1991, 11, 1543-1547.
24. Ita M, Halicka HD, Tanaka T, Kurose A, Ardelt B, Shogen K: Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines. Cancer Biol Ther, 2008, 7, 1104-1108.
25. Kakehi Y, Yoshida O, Segawa T, Kanematsu A, Hiura M, Shichiri Y: Intraarterial chemotherapy for metastatic renal cell carcinomas: combination with MDR-overcoming agents. Hinyokika Kiyo, 1994, 40, 925-929. (Pubitemid 24353541)
26. Kato T, Suzumura Y: Potentiation of antitumor activity of vincristine by the biscoclaurine alkaloid cepharanthine. J Natl Cancer Inst, 1987, 79, 527-532. (Pubitemid 17126591)
27. Katsui K, Kuroda M, Wang Y, Komatsu M, Himei K, Takemoto M: Cepharanthin enhances adriamycin sensitivity by synergistically accelerating apoptosis for adriamycin-resistant osteosarcoma cell lines, SaOS2-AR and SaOS2 F-AR. Int J Oncol, 2004, 25, 47-56.
28. Kaufmann SH, Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res, 2000, 256, 42-49. (Pubitemid 30211165)
29. Kikukawa Y, Okuno Y, Tatetsu H, Nakamura M, Harada N, Ueno S: Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a biscoclaurine alkaloid. Int J Oncol, 2008, 33, 807-814.
30. Kimoto T, Suemitsu K, Nakayama H, Komori E, Ohtani M, Ando S: Therapeutic experience of venomous snakebites by the Japanese viper (Agkistrodon halys Blomhoffii) with low dose of antivenin: report of 43 consecutive cases. Nippon Geka Hokan, 1997, 66, 71-77. (Pubitemid 28410969)
31. Kisara S, Hayashi A, Maekawa I, Furusawa S, Takayanagi Y, Sasaki K: Assay of flow cytometry for the effect of cepharanthine on resistance to doxorubicin. Yakugaku Zasshi, 1992, 112, 837-845. (Pubitemid 23022529)
32. Kobayashi M, Katayama T, Ochiai S, Yoshida M, Kaito K, Masuoka H: High-dose cepharanthin therapy of idiopathic thrombocytopenic purpura. Rinsho Ketsueki, 1992, 33, 405-407.
33. Kogure K, Goto S, Abe K, Ohiwa C, Akasu M, Terada H: Potent antiperoxidation activity of the bisbenzylisoquinoline alkaloid cepharanthine: the amine moiety is responsible for its pH-dependent radical scavenge activity. Biochim Biophys Acta, 1999, 1426, 133-142. (Pubitemid 29027876)
34. Kogure K, Tsuchiya K, Abe K, Akasu M, Tamaki T, Fukuzawa K: Direct radical scavenging by the bisbenzylisoquinoline alkaloid cepharanthine. Biochim Biophys Acta, 2003, 1622, 1-5. (Pubitemid 36776343)
35. Kohno H, Seyama Y, Yamashita S, Akasu M, Inoue H: Effects of cepharanthine on experimental nasal allergy. Nippon Yakurigaku Zasshi, 1986, 88, 71-76. (Pubitemid 17182940)
36. Kohno H, Inoue H, Seyama Y, Yamashita S, Akasu M: Mode of the anti-allergic action of cepharanthine on an experimental model of allergic rhinitis. Nippon Yakurigaku Zasshi, 1987, 90, 205-211. (Pubitemid 18083863)
37. Kometani M, Kanaho Y, Sato T, Fujii T: Inhibitory effect of cepharanthine on collagen-induced activation in rabbit platelets. Eur J Pharmacol, 1985, 111, 97-105. (Pubitemid 15097845)
38. Kondo Y, Imai Y, Hojo H, Hashimoto Y, Nozoe S: Selective inhibition of T-cell-dependent immune responses by bisbenzylisoquinoline alkaloids in vivo. Int J Immunopharmacol, 1992, 14, 1181-1186.
39. Kono K, Takahashi JA, Ueba T, Mori H, Hashimoto N, Fukumoto M: Effects of combination chemotherapy with biscoclaurine-derived alkaloid (cepharanthine) and nimustine hydrochloride on malignant glioma cell lines. J Neurooncol, 2002, 56, 101-108. (Pubitemid 34272300)
40. Kulka M: Bisbenzylisoquinoline alkaloids. In: The Alkaloids. Chemistry and Physiology, Ed. Manske R, Vol. 4. Academic Press, London, New York, 1965, 233.
41. Lee SH, Lee SY, Son DJ, Lee H, Yoo HS, Song S: Inhibitory effect of 2′-hydroxycinnamaldehyde on nitric oxide production through inhibition of NF-κB activation in RAW 264.7 cells. Biochem Pharmacol, 2005, 69, 791-799. (Pubitemid 40248621)
42. Masuda M, Tominaga R, Nokashima A, Mayumi H, Morita S, Kono H: Clinical assessment of complement activation and leukocyte kinetics during cardiopulmonary bypass: the effect of cepharanthine. Kyobu Geka, 1993, 46, 845-849.
43. Morita K, Nakamura M, Nagamachi M, Kishi T, Miyachi Y: Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies. J Dermatol, 2002, 29, 661-664. (Pubitemid 35334015)
44. Mukai M, Che X, Furukawa T, Sumizawa T, Aoki S, Ren X: Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. Cancer Sci, 2003, 94, 557-563. (Pubitemid 36849722)
45. Murakami K, Cox RA, Hawkins HK, Schmalstieg FC, McGuire RW, Jodoin JM, Traber LD, Traber DL: Cepharanthin, an alkaloid from Stephania cepharantha, inhibits increased pulmonary vascular permeability in an ovine model of sepsis. Shock, 2003, 20, 46-51.
46. Nagano M, Kanno T, Fujita H, Muranaka S, Fujiwara T, Utsumi K: Cepharanthine, an anti-inflammatory drug, suppresses mitochondrial membrane permeability transition. Physiol Chem Phys Med NMR, 2003, 35, 131-143. (Pubitemid 39504692)
47. Nagatsuka S, Nakazawa T: Effect of membrane-stabilizing agents, cholesterol and cepharanthine, on radiation-induced lipid peroxidation and permeability in liposomes. Biochim Biophys Acta, 1982, 691, 171-177. (Pubitemid 13232481)
48. Nakajima A, Yamamoto Y, Taura K, Hata K, Fukumoto M, Uchinami H: Beneficial effect of cepharanthine on overcoming drug-resistance of hepatocellular carcinoma. Int J Oncol, 2004, 24, 635-645.
49. Nakatsu T: A study on the effect of cepharanthin, a biscoclaurine alkaloid, on enhancement of mitogen-induced histidine decarboxylase activity in mice spleens and the effect of histamine on the production of cytokines. Nippon Yakurigaku Zasshi, 1995, 105, 209-219.
50. Nakayama S, Matsushita A, Ichiba S, Nagai K: Clinical evaluation of cepharanthin for chronic idiopathic thrombocytopenic purpura. Rinsho Ketsueki, 1992, 33, 408-409.
51. Nishida H, Tsuchiya H: Nodular muscular sarcoidosis vanished during oral cepharanthine treatment. Cent Jap J Orthopaed Surg Traum, 2007, 50, 1133-1134.
52. Niwa Y: Effect of cepharanthine on alopecia areata. Hifuka Kiyo, 1969, 64, 47-52.
53. Nomoto S, Imada H, Ohguri T, Yahara K, Kato F, Morioka T: Effect of cepharanthin in preventing radiation induced normal tissue damage in prostate cancer. Gan To Kagaku Ryoho, 2004, 31, 1063-1066.
54. Ohno N, Kreitman RJ, Saito T, Masamoto I, Uozumi K, Hanada S: Augmentation of the activity of an immunotoxin, anti-Tac(Fv)-PE40KDEL, in T cell lines infected with human T cell leukemia virus type-I. Leuk Lymphoma, 2002, 43, 885-888. (Pubitemid 34428679)
55. Ohta T, Morita K: Effect of cepharanthin on radiotherapy induced leukopenia. Rinsho Hoshasen, 1990, 35, 471-474. (Pubitemid 20213108)
56. Okada K, Sakusabe N, Kobayashi A, Hoshi N, Sato K: Prevention of lung metastasis by intra-tumoral injection of cepharanthin and staphylococcal enterotoxin B in transplantable rat osteosarcoma. Jpn J Cancer Res, 1999, 90, 928-933. (Pubitemid 29500430)
57. Okamoto M, Ono M, Baba M: Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. AIDS Res Hum Retroviruses, 1998, 14, 1239-1245. (Pubitemid 28488934)
58. Okamoto M, Okamoto T, Baba M: Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells. Antimicrob Agents Chemother, 1999, 43, 492-497. (Pubitemid 29109508)
59. Ono M, Urabe T, Okamoto Y, Murakami H, Tatemoto A, Ohno S: Augmentation of murine organ-associated natural immune responses by cepharanthin. Gan To Kagaku Ryoho, 1988, 15, 127-133. (Pubitemid 18042136)
60. Ono M, Tanaka N: Positive interaction of bisbenzylisoquinoline alkaloid, cepharanthin, with vinca alkaloid agents against human tumors. In Vivo, 1997, 11, 233-241. (Pubitemid 27348109)
61. Saito R, Tsuchiya S, Ishizuka T, Fueki N, Ezawa K, Minato K: Clinical effects of cepharanthin (Ceph.) on leukopenia by chemotherapy in lung cancer patients. Nippon Gan Chiryo Gakkai Shi, 1989, 24, 2587-2593. (Pubitemid 20081480)
62. Sato T, Kometani M, Fujii T: Certain membrane-interacting amphiphiles inhibit aggregation and reverse shape change of rabbit platelets pre-activated with arachidonic acid through dissociation of cytoskeletal assembly. Thromb Res, 1987, 46, 587-592. (Pubitemid 17096472)
63. Sato T, Morita I, Fujita H, Ono M, Kimishima A, Tomiyama J, Murota S: Pharmacological characterization of cepharanthin in chronic idiopathic thrombocytopenic purpura. Platelets, 2001, 12, 156-162. (Pubitemid 32299584)
64. Shimazu R, Tanaka G, Tomiyama R, Kuratomi Y, Inokuchi A: Cepharanthin effect on radiation-induced xerostomia and taste disorder in patients with head and neck cancer. Nippon Jibiinkoka Gakkai Kaiho, 2009, 112, 648-655.
65. Shiraishi N, Arima T, Aono K, Inouye B, Morimoto Y, Utsumi K: Inhibition by biscoclaurine alkaloid of lipid peroxidation in biological membranes. Physiol Chem Phys, 1980, 12, 299-305.
66. Shiraishi N, Akiyama S, Nakagawa M, Kobayashi M, Kuwano M: Effect of bisbenzylisoquinoline (biscoclaurine) alkaloids on multidrug resistance in KB human cancer cells. Cancer Res, 1987, 47, 2413-2416. (Pubitemid 17099206)
67. Song Y, Xia W, Jiang J, Wang Q: Reversal of multidrug resistance in drug-resistant cell line EAC/ADR by cepharanthine hydrochloride and its mechanism. Yao Xue Xue Bao, 2005, 40, 204-207. (Pubitemid 40627128)
68. Suzuki S, Abe R, Nihei M, Kimijima I, Tsuchiya A, Nomizu T: Efficacy of Cepharanthin for preventing leukopenia and thrombocytopenia induced by chemotherapy in breast cancer patient - prospective randomized study. Gan To Kagaku Ryoho, 1990, 17, 1195-1200. (Pubitemid 20378247)
69. Suzuki R, Hara M, Shindoh J, Matsumoto S, Noda Y, Gonda H: Effects of cepharanthin on leukopenia and thrombocytopenia induced by chemotherapy in lung cancer patients. Gan To Kagaku Ryoho, 1992, 19, 647-652.
70. Tamatani T, Azuma M, Motegi K, Yoshida H: Enhanced apoptosis induced by radiation and cepharanthine in human oral squamous cell carinoma cells. Jap J Cancer Res, 2006, 65, 498.
71. Tamez PA, Lantvit D, Lim E, Pezzuto JM: Chemosensitizing action of cepharanthine against drug-resistant human malaria, Plasmodium falciparum. J Ethnopharmacol, 2005, 98, 137-142. (Pubitemid 40349178)
72. Terasaki M, Abe T, Miyagi N, Ogo E, Shigemori M: Feasibility and response to 1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride chemotherapy with pre-treated procarbazine for elderly patients with newly diagnosed glioblastoma. J Neurooncol, 2007, 81, 265-269. (Pubitemid 46165330)
73. Titheradge MA: Nitric oxide in septic shock. Biochim Biophys Acta, 1999, 1411, 437-455.
74. Tsukikawa S, Oikawa H, Satoh T, Morikubo M, Komoriyama H, Hagiwara M: The effect of cepharanthin on adjuvant chemotherapy induced bone marrow suppression in patients with breast cancer. Gan To Kagaku Ryoho, 1990, 17, 645-648. (Pubitemid 20253395)
75. Tsunemori H, Kitamura Y, Taniguchi S, Okazoe H, Taoka R, Inui M, Sugimoto M, Kakehi Y: Experience using intra-arterial chemotherapy in combination with MDR-reversing agent for bone and soft-tissue metastases from renal cell carcinoma (Japanese). Nish J Urol, 2008, 70, 245-249.
76. Ushiki N, Jobo T, Shimoda T, Kuramoto H, Arai M: Effects of cepharanthin on leukopenia and thrombocytopenia caused by CDDP-ACR-CPA therapy of ovarian cancer. Gan To Kagaku Ryoho, 1988, 15, 2701-2706. (Pubitemid 18259883)
77. Wu J, Suzuki H, Zhou YW, Liu W, Yoshihara M, Kato M, Akhand AA et al.: Cepharanthine activates caspases and induces apoptosis in Jurkat and K562 human leukemia cell lines. J Cell Biochem, 2001, 82, 200-214. (Pubitemid 32606284)
78. Yamazaki T, Shibuya S, Akatsuka J: Pediatric recurrent ITP case: treatment and its application at the time of rethrombocytopenia. Jpn J Pediatr Oncol, 2007, 44, 325.
79. Yasukawa K, Takido M, Takeuchi M, Akasu M, Nakagawa S: Cepharanthine inhibits two-stage tumor promotion by 12-O-tetradecanoylphorbol 13-acetate and mezerein on skin tumor formation in mice initiated with 7,12-dimethylbenz[a] anthracene. J Cancer Res Clin Oncol, 1991, 117, 421-424.